AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21168000
Drug: High-dose tirofiban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose tirofiban (HDT)
Trial: 9748099
Drug: Glucide content
RxNorm normalized name: lauroyl/myristoyl methyl glucamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucide content more than 150 g
Trial: 17921791
Drug: Topical nimesulide
RxNorm normalized name: nimesulide Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nimesulide gel 1% applied 3 times a day for 30 days
Trial: 17921791
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel applied 3 times a day for 30 days
Trial: 17921791
Drug: Topical nimesulide
RxNorm normalized name: nimesulide Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nimesulide gel 1%
Trial: 15656699
Drug: Posaconazole 800
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole 800 mg as a single dose (regimen A)
Trial: 15656699
Drug: Posaconazole 400
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole 400 mg every 12 hours (regimen B)
Trial: 6939000
Drug: Dextroamphetamine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine 0.25 mg/kg
Trial: 6939000
Drug: Dextroamphetamine 0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine 0.50 mg/kg
Trial: 28648412
Drug: Restrictive hydration
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive hydration with norepinephrine administration (1ml/kg/h initially, then 3ml/kg/h crystalloid infusion after cystectomy)
Trial: 28648412
Drug: Liberal hydration
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberal hydration (6ml/kg/h standard crystalloid infusion throughout surgery)
Trial: 24345529
Drug: Nepafenac 0.3%
RxNorm normalized name: NEPAFENAC 0.3% OPH SUSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nepafenac 0.3% once daily
Trial: 14635083
Drug: Palonosetron 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron 0.75 mg
Trial: 19605507
Drug: Dexamethasone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (20 mg for patients receiving paclitaxel, 8 mg for those not receiving paclitaxel)
Trial: 9649640
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) 15 mg/kg
Trial: 9504319
Drug: Conventional weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional weight reduction treatment
Trial: 11271224
Drug: PUVA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUVA therapy (8‐methoxypsoralen and UVA irradiation)
Trial: 3069135
Drug: Isoproterenol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoproterenol infusion at 1 microgram/min for up to 20 min
Trial: 3069135
Drug: Isoproterenol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoproterenol infusion (mean dosage of 18.5 ng/min/kg)
Trial: 3069135
Drug: Panic attacks
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Panic attacks during isoproterenol infusions
Trial: 27824264
Drug: Luphere 3M
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luphere 3M Depot (leuprolide acetate dose of 11.25 mg)
Trial: 27824264
Drug: Lucrin Depot
RxNorm normalized name: Primoteston Depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lucrin Depot (leuprolide acetate dose of 11.25 mg)
Trial: 26609031
Drug: Oral 25
RxNorm normalized name: Neoral 25mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 25 mg dexketoprofen trometamol
Trial: 26609031
Drug: Two puff
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two puff lidocaine sprays on cervical mucosa
Trial: 12834936
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg pethidine
Trial: 26609031
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg intravenous paracetamol
Trial: 10703393
Drug: Tacrolimus plus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus plus 'low-dose' MMF (TMBIR)
Trial: 10703393
Drug: Neoral plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoral plus 'low-dose' MMF (NMBIR)
Trial: 7037035
Drug: Budesonide, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide, 200 micrograms twice daily
Trial: 7037035
Drug: Beclomethasone dipropionate,
RxNorm normalized name: Beclomethasone Dipropionate, compounding powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate, 100 micrograms four times daily
Trial: 19818720
Drug: Purified vero
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified vero cell rabies vaccine (PVRV, Verorab)
Trial: 28199892
Drug: Brief therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief therapy (BT)
Trial: 15549275
Drug: Whole drink
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole drink (containing 37.5 g glucose, 75 mg caffeine, ginseng and ginkgo biloba)
Trial: 11778791
Drug: pMDI+S (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pMDI+S (100 microg dose(-1) pressurized metered-dose inhaler with a spacer)
Trial: 3318428
Drug: Nabumetone 1,000
RxNorm normalized name: nabumetone 1,000 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabumetone 1,000 mg taken at bedtime
Trial: 25311370
Drug: Control arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control arm (no access to the website, weekly telephone call as attention-strategy)
Trial: 23900058
Drug: Oral supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral supplementation of a bacterial lysate between week 5 and the end of month 7 (intervention group)
Trial: 19761514
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (light still touch, same duration as intervention)
Trial: 1294028
Drug: Overall early
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall early instillation therapy
Trial: 30620771
Drug: Hypothetical community-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothetical community-based health insurance (CBHI) schemes with various benefit package components including insurance coverage for medical consultations, hospitalizations, traffic accidents, pharmaceuticals, transportation, premiums, and prepaid discounts.
Trial: 26920602
Drug: Continued novel
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued novel oral anticoagulant (dabigatran, rivaroxaban, or apixaban)
Trial: 26920602
Drug: Continued novel
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued novel oral anticoagulant
Trial: 26920602
Drug: Interrupted novel
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interrupted novel oral anticoagulant
Trial: 24457590
Drug: Problem-solving therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-solving therapy (PST; 12 total sessions, N=53)
Trial: 17197012
Drug: Postoperative adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative adjuvant whole pelvic radiation therapy (WPRT)
Trial: 10422040
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine estrogen 0.625 mg daily plus progestogen (norgestrel) 150 micrograms for the last 12 days of each 28 day cycle
Trial: 343738
Drug: Propranolol administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol administered 1 to 2 hours prior to operation (Group 2)
Trial: 26963897
Drug: DHEA 25
RxNorm normalized name: GNP DHEA 25mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA 25 mg three times daily for 12 weeks before IVF/ICSI cycles
Trial: 17260879
Drug: Benzodiazepine drugs
RxNorm normalized name: 1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one
DrugBank: Nitrazepam (DB01595)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzodiazepine drugs (group 2)
Trial: 17260879
Drug: Benzodiazepine and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzodiazepine and GABAergic drugs (group 3)
Trial: 11682404
Drug: Large-dose IV
RxNorm normalized name: Bos taurus large intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large-dose IV meperidine (target plasma concentration of 0.8 microg/mL)
Trial: 11682404
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of buspirone (30 mg) and meperidine (0.4 microg/mL)
Trial: 9728378
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (n = 51)
Trial: 3192038
Drug: 40‐g low‐protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40‐g low‐protein diet (LPD)
Trial: 354471
Drug: Carbenoxolone 50
RxNorm normalized name: carbenoxolone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbenoxolone 50 mg three times daily
Trial: 23692696
Drug: Vaccination with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination with phase I Coxiella burnetii vaccine (Coxevac-Ceva Sante Animale) during advanced pregnancy
Trial: 23692696
Drug: Vaccination with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination with phase I Coxiella burnetii vaccine
Trial: 17524937
Drug: CsA (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA (8 mg/kg/d) plus MMF (30 mg/kg/d) and prednisolone (1 mg/kg/d)
Trial: 12568014
Drug: Dihydroartemisinin/pyronaridine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin/pyronaridine combination
Trial: 9825744
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 15 mg weekly i.m. injections for 1 year
Trial: 9825744
Drug: Gold sodium
RxNorm normalized name: Gold Sodium Thiomalate
DrugBank: Gold (DB14154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gold sodium thiomalate (GSTM) 50 mg weekly i.m. injections for 1 year
Trial: 7854994
Drug: Loratadine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loratadine (10 mg daily for 28 days)
Trial: 809805
Drug: Low-dose EHDP
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose EHDP
Trial: 29045535
Drug: selumetinib 75
RxNorm normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: selumetinib 75 mg b.i.d. plus docetaxel 60 mg/m2 (SEL+DOC 60)
Trial: 29045535
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus docetaxel 75 mg/m2 (PBO+DOC 75)
Trial: 20941455
Drug: Apixaban 2.5
RxNorm normalized name: apixaban 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban 2.5 mg once daily
Trial: 20941455
Drug: Enoxaparin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (40 mg once‐daily or 30 mg twice‐daily)
Trial: 17296165
Drug: Habituation Based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Habituation Based Exposure Therapy (HBET)
Trial: 7820960
Drug: CDP-choline (cytidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDP-choline (cytidine diphosphate choline) administered daily for one week after a single intravenous injection.
Trial: 24499168
Drug: Dapagliflozin 10
RxNorm normalized name: dapagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 10 mg + metformin
Trial: 22540883
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + metformin
Trial: 18496564
Drug: Efalizumab (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efalizumab (subcutaneous treatment for 12 weeks)
Trial: 24223344
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) ketamine 0.5mg/kg
Trial: 24223344
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) ketamine 0.5 mg/kg
Trial: 20697700
Drug: Ritonavir 300
RxNorm normalized name: nirmatrelvir / ritonavir 300 MG /100 MG ; 150 MG / 100 MG Dose Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir 300 mg b.i.d. for 4 days
Trial: 20697700
Drug: Lopinavir/ritonavir 400/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir 400/100 mg b.i.d. for 4 days
Trial: 18441036
Drug: Robot-mediated therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-mediated therapy
Trial: 18441036
Drug: Sling suspension
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sling suspension phase
Trial: 12673669
Drug: Testim (1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testim (1% testosterone topical gel, 50 mg)
Trial: 12673669
Drug: AndroGel (1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AndroGel (1% testosterone topical gel, 50 mg)
Trial: 8907096
Drug: Therapeutic treatments
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic treatments (3 brief treatments for depression)
Trial: 27682852
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab (IVR) 0.25 mg
Trial: 27682852
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (IVB) 0.625 mg
Trial: 25491116
Drug: 1% pimecrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% pimecrolimus cream
Trial: 19541679
Drug: Dexmedetomidine 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 2 microg kg(‐1) in normal saline 1 ml
Trial: 17478142
Drug: Nicorandil 12
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil 12 mg intravenously before PCI
Trial: 15926604
Drug: COX-2 selective
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: COX-2 selective inhibitors
Trial: 6357035
Drug: Both inpatient
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both inpatient and outpatient treatment
Trial: 22055006
Drug: Single-injection PVB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-injection PVB (20 mL 0.5% bupivacaine with 1:200,000 epinephrine at T6, n = 25)
Trial: 15091194
Drug: Alpha-tocopherol supplementation
RxNorm normalized name: alpha tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-tocopherol supplementation (1000 mg/day for 3 months)
Trial: 12243810
Drug: q.d. RT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: q.d. RT (60 Gy in 30 daily fractions) with etoposide and cisplatin (EP)
Trial: 9828758
Drug: 0.75 g
RxNorm normalized name: Allantoin 0.75 g in 75 g TOPICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 g fructose/kg body weight
Trial: 9828758
Drug: 0.75 g
RxNorm normalized name: Allantoin 0.75 g in 75 g TOPICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 g starch/kg body weight
Trial: 7926574
Drug: Intracervical gel
RxNorm normalized name: eladocagene exuparvovec
DrugBank: Eladocagene exuparvovec (DB16780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracervical gel containing 0.5 mg PgE2
Trial: 7926574
Drug: Intravaginal tablet
RxNorm normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal tablet containing 3 mg PgE2
Trial: 27017282
Drug: G-CSF 150
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF 150 µg/body/day
Trial: 27017282
Drug: G-CSF 300
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF 300 µg/body/day
Trial: 25693332
Drug: Sugammadex 4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 4.0 mg . kg‐1
Trial: 19204524
Drug: Problem drug
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem drug use
Trial: 19204524
Drug: Professional treatment
RxNorm normalized name: ANHYDROUS DEXTROSE 5 g in 20 g / CURCUMIN 4 g in 20 g / ICOSAPENT 3 g in 20 g / CHOLECALCIFEROL 2 g in 20 g TOPICAL GEL [SOUTH MOON Propolis Professional Treatment Gel]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Professional treatment for substance use
Trial: 15000887
Drug: Propofol (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (0.1 mg/kg/min) intravenously for anesthesia maintenance
Trial: 15000887
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received fentanyl 10 microg/kg intravenously and inhaled enflurane (1 %‐1.5 %)
Trial: 2522405
Drug: Low initial
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low initial dosage of acitretin (10, 30, 50 mg/day)
Trial: 2522405
Drug: Constant dosage
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant dosage of acitretin (30 mg/day)
Trial: 2522405
Drug: High initial
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High initial dosage of acitretin (50, 30, 10 mg/day)
Trial: 2522405
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (10, 30, or 50 mg/day) during open phase
Trial: 24906471
Drug: 5-methyltetrahydrofolate (5-MTHF)
RxNorm normalized name: 5-METHYLTETRAHYDROFOLIC ACID
DrugBank: 5-methyltetrahydrofolic acid (DB04789)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-methyltetrahydrofolate (5-MTHF) 15 mg/day for 3 weeks
Trial: 23913405
Drug: Clopidogrel napadisilate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel napadisilate 75 mg once daily
Trial: 23913405
Drug: Clopidogrel bisulfate
RxNorm normalized name: Clopidogrel Bisulfate
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel bisulfate 75 mg once daily
Trial: 21871589
Drug: Denosumab 0.03,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab 0.03, 0.1, 0.3, 1.0 or 3.0 mg/kg
Trial: 16439874
Drug: Therapeutic immunization
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic immunization with four boosts of ALVAC 1433 and HIV‐LIPO‐6T vaccines followed by three cycles of subcutaneous interleukin‐2
Trial: 16439874
Drug: Antiretroviral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral treatment alone (Control)
Trial: 9411672
Drug: Postoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative treatment with 500 mg of 17‐1A antibody, followed by four 100 mg infusions each month.
Trial: 2871538
Drug: Physiologic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiologic saline solutions
Trial: 26222393
Drug: PDPH receiving
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDPH receiving a blood patch
Trial: 19131059
Drug: Homeostasis model
RxNorm normalized name: CALCIUM HOMEOSTASIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeostasis model assessment of insulin resistance in women with PCOS
Trial: 15668606
Drug: CEE 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE 0.625 mg/day + MPA 5 mg/day
Trial: 9394855
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate 40 mg q.i.d.
Trial: 1674677
Drug: Metocurine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metocurine 0.1 mg.kg‐1 plus pancuronium 0.02 mg.kg‐1 (M-P)
Trial: 31023525
Drug: Reduction of
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction of daily sugar intake to less than 25 g
Trial: 21188440
Drug: Midazolam and
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam and Diclofenac (0.05 mg/kg midazolam and 1.5 mg/kg diclofenac, 15 min before surgical incision)
Trial: 21188440
Drug: Diclofenac (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (1.5 mg/kg diclofenac, 15 min before surgical incision)
Trial: 9659700
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg Dinoprostongel (Prepidil)
Trial: 9659700
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg Gemeprost vaginal suppositories (Cergem)
Trial: 9659700
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg Dinoprostongel (repeated applications)
Trial: 9659700
Drug: Repeated therapy
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated therapy with Gemeprost